Skip To Main Content
Dromme IV on Muck Rack

Dromme IV

Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work. Claim your profile

Get in touch with Dromme

Contact Dromme, search articles and posts on X, monitor coverage, and track replies from one place.

Learn more about Muck Rack

Actions

Share this page

Is this you?

As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile

Articles

Quantifying how single dose Ad26.COV2.S vaccine efficacy depends on Spike sequence features

|
By de Sousa LP, Bekker LG, Gars ML, Dromme IV
| ncbi.nlm.nih.gov
This is a preprint. It has not yet been peer reviewed by a journal. The National Library of Medicine is running a pilot to include preprints that result from research funded by NIH in PMC and PubMed. Display options Abstract It is of interest to pinpoint SARS-CoV-2 sequence features defining vaccine resistance. In the ENSEMBLE randomized, placebo-controlled phase 3 trial, estimated single-dose Ad26.COV2.S vaccine efficacy (VE) was 56% against moderate to severe-critical COVID-19.
Open in Who Shared Issue with article?
See all 1 articles